ALS News Today

ALS News Today is a daily online news platform dedicated to keeping ALS patients and their caregivers informed about the newest scientific research and advancements related to the disease. Despite ongoing research and development efforts in ALS treatment, health media often overlooks this important information. To address this gap, ALS News Today employs a skilled team of researchers and journalists who gather the latest news on ALS and present it in an accessible way for patients.

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#613873

United States

#288321

Health/Health Conditions and Concerns

#791

Traffic sources

Monthly visitors

Articles

How I use a shoehorn to help me live well with ALS

1 week ago | alsnewstoday.com | Dagmar Munn |Kristin Neva

The other day, my husband spotted me putting on my sneakers while using a long shoehorn and asked, “Wouldn’t that be a lot easier if we got you a pair of those new step-in shoes?”I’ll admit that living with ALS has me continually thinking of ways to make my life easier. But it’s also made me super picky about my shoes. So without looking up, I mumbled, “I don’t know, maybe.
SOD1-ALS disease progression may slow with RAG-17: Final trial data

1 week ago | alsnewstoday.com | Steve Bryson |Patricia Inacio |Esteban Cerezo |Lindsey Shapiro

An experimental candidate by Ractigen Therapeutics to treat amyotrophic lateral sclerosis (ALS) linked to mutations in the SOD1 gene has shown promising signs of slowed functional decline and stable or improved breathing in ALS patients of a small early trial. The therapy, RAG-17, also significantly reduced blood levels of neurofilament light chain (NfL), a biomarker of nerve damage, and demonstrated target engagement, as indicated by a drop in SOD1 protein levels.
AAN 2025: PrimeC reduces miRNAs linked to ALS progression

1 week ago | alsnewstoday.com | Margarida Maia |Kristin Neva |Katherine Poinsatte

Neurosense Therapeutics’ oral therapy PrimeC significantly reduces blood levels of miRNAs — molecules involved in regulating gene activity — associated with disease progression and survival in people with amyotrophic lateral sclerosis (ALS). That’s according to six-month biomarker data from the Phase 2b PARADIGM clinical trial (NCT05357950), in which 68 adults with ALS were randomly assigned to receive either PrimeC or a placebo for six months, followed by one year on the therapy.
Why it's good to have a backup wheelchair

2 weeks ago | alsnewstoday.com | Kristin Neva |Andrea Lobo

We didn’t realize how much my husband Todd’s comfort depended on his custom-fit power wheelchair until he had to go without it. A few weeks ago, Todd, who has ALS, decided to order a new wheelchair after finding out that his 11-year-old Permobil C300 isn’t fully compatible with the latest eye-gaze technology that he’d need to safely drive the chair. The new chair is months from arriving, so in the meantime, we needed to repair his current one.
CREB3 protein identified as potential ALS treatment target

2 weeks ago | alsnewstoday.com | Marisa Wexler

A rare mutation that leads to abnormally high activity of the CREB3 protein is associated with a reduced risk of developing amyotrophic lateral sclerosis (ALS) and people with ALS who carry this mutation progress significantly more slowly and live longer than those who don’t. That’s according to the study, “CREB3 gain of function variants protect against ALS,” which was published in Nature Communications.
ALS patient treated with TRE-515 in expanded access program

2 weeks ago | alsnewstoday.com | Andrea Lobo

A patient with late-stage amyotrophic lateral sclerosis (ALS) was treated with TRE-515, Trethera’s investigational therapy, under a U.S. Food and Drug Administration (FDA) expanded access program, the company has announced. The program enables patients with life-threatening conditions, including ALS, to receive experimental therapies outside clinical trials when no satisfactory alternatives exist.
Trace plans ALS trial of UNC13A treatment with help from AI tools

2 weeks ago | alsnewstoday.com | Lindsey Shapiro

Trace Neuroscience plans to test genomic medicine that targets the UNC13A protein in people with amyotrophic lateral sclerosis (ALS) in a Phase 1/2 clinical trial that will be supported by artificial intelligence (AI)-powered tools from Unlearn. Unlearn’s Digital Twin Generator for ALS (ALS DTG) will be used to create a “digital twin” for each trial participant, this way predicting how their disease would progress under standard care or in a placebo group of a clinical trial.
Edaravone is more than antioxidant in ALS treatment: Early study

3 weeks ago | alsnewstoday.com | Steve Bryson

Edaravone, an approved amyotrophic lateral sclerosis (ALS) therapy sold as Radicava and Radicava ORS, may exert neuroprotective effects by correcting a key molecular feature of ALS, a cell-based study shows. Specifically, edaravone was found to correct the abnormal localization of TDP-43, a protein that is involved in many cellular functions but often gets mislocalized within cells in ALS and forms into toxic clumps that contribute to neurodegeneration in nearly all patients.
A short break from caregiving was good for my mental health

3 weeks ago | alsnewstoday.com | Kristin Neva |Marisa Wexler

Last week for spring break, I traveled with my son from snowy Michigan to sunny Florida. Siesta Key was just as beautiful as I remembered from 15 years ago when my husband, Todd, and I vacationed there with our two small children, along with Todd’s parents and my brother who was living there. We rented a condo and spent time on the beach with its soft, white, powdery sand, and my brother and I went parasailing.
Silence ALS treats 9 patients' ultra-rare ALS caused by CHCHD10 mutations

3 weeks ago | alsnewstoday.com | Margarida Maia |Lindsey Shapiro |Patricia Inacio

Nine patients with an ultra-rare form of amyotrophic lateral sclerosis (ALS) caused by mutations in the CHCHD10 gene were treated with an experimental antisense oligonucleotide (ASO) that’s designed to silence the disease-causing mutations. The treatment was developed as part of Silence ALS, an initiative that designs ASOs, that is, short strands of genetic material, for carriers of ultra-rare, disease-causing genetic mutations.